Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD)
ConditionHuntington Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorNeuromed IRCCS
About this trial
Huntington's disease (HD) is a neurodegenerative pathology characterized by choreic hyperkinesias which represent the typical motor symptom and are represented by involuntary, aimless, irregular, recurrent, unpredictable and non-rhythmic movements of the trunk, face and limbs.
Non-invasive brain neuromodulation has been proposed as a possible treatment for involuntary movements in several clinical conditions including HD.
The objective of the study is to evaluate the effect of home treatment with repeated sessions of transcranial static magnetic field stimulation (tSMS) in safely reducing choreic hyperkinesis in HD patients.
Eligibility criteria
Qualifiers
Diagnosis of HD genetically confirmed (number of CAG triplets ≥36)
Presence of chorea movements quantified with a score ≥ 10 on the sum of the scores of the subscale of the Unified Huntington's Disease Rating Scale (UHDRS) for the evaluation of maximum chorea for the facial, oro-bucco-lingual, truncal, four limbs districts
Ability to provide written informed consent
No changes in drug therapy in the 8 weeks prior to the baseline visit
Disqualifiers
Contraindications to exposure to magnetic fields
Patients who are pregnant or breastfeeding
Presence of significant risk of suicidal behavior
Patients who have received an investigational drug in a clinical trial within 30 days of the baseline visit or have planned to use such an investigational drug during the study
Trial design
Treatments tested in this trial
- Portable ergonomic helmet for real tSMS
- portable ergonomic helmet for placebo tSMS
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov